KRAS and familial pancreatic carcinoma: Almost 90% of pancreatic cancer patients express mutant KRAS (G12D), which has been considered as the initiator of PDAC.38 Although novel KRAS‐PDEdelta inhibitors seem to inhibit KRAS ability,39 the development of small molecule therapy targeting KRAS remains unsuccessful.40, 41 Thus, targeting the downstream of mutant KRAS is a candidate therapy for PDAC.